Last reviewed · How we verify

Tesaro, Inc. — Portfolio Competitive Intelligence Brief

Tesaro, Inc. pipeline: 0 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 1 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo matching dostarlimab Placebo matching dostarlimab phase 3 PD-1 inhibitor PD-1 Oncology
Dostarlimab (TSR-042) Dostarlimab (TSR-042) phase 3 PD-1 inhibitor PD-1 Oncology
Placebo matching Niraparib Placebo matching Niraparib phase 3 PARP inhibitor (reference: niraparib) PARP1/PARP2 (reference target) Oncology
Active comparator: Niraparib Active comparator: Niraparib phase 3 PARP inhibitor PARP1, PARP2 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Tianjin Medical University Cancer Institute and Hospital · 2 shared drug classes
  2. Hospices Civils de Lyon · 2 shared drug classes
  3. Sanofi · 2 shared drug classes
  4. The Netherlands Cancer Institute · 2 shared drug classes
  5. Addpharma Inc. · 1 shared drug class
  6. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  7. ATGC Co., Ltd. · 1 shared drug class
  8. AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tesaro, Inc.:

Cite this brief

Drug Landscape (2026). Tesaro, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tesaro-inc. Accessed 2026-05-14.

Related